|
|
TMAO通过激活NLRP3炎症小体在HCC发展中的作用
|
Abstract:
目的：探讨TMAO促进NLRP3炎症小体活化对小鼠肝癌进展的影响及其潜在机制。方法：12只6~8周龄SPF级C57BL/6J小鼠，通过肝内接种Hepa1-6细胞构建小鼠肝癌原位模型。随机分为对照组(NC组)与TMAO组，每组6只。在接种后1周后，TMAO组予腹腔注射TMAO溶液，对照组腹腔注射等体积的生理盐水，期间记录小鼠体重变化。4周后分离并观察肝脏肿瘤大小及称取质量，确定TMAO对小鼠肝脏肿瘤进展的影响。检测血清IL-1β、IL-18水平，HE染色观察肝组织病理变化，实时荧光定量PCR (RT-PCR)检测肝组织NLRP3、Caspase-1及GSDMD的mRNA水平。结果：小鼠原位肝癌模型构建成功。与对照组相比，TMAO促进了小鼠肝肿瘤生长(P < 0.05)，血清IL-1β、IL-18水平升高(P < 0.05)，肝组织NLRP3、Caspase-1及GSDMD的mRNA表达增强(P < 0.05)。结论：TMAO通过NLRP3/GSDMD信号通路释放炎症因子，促进肝癌进展。
Objective: To investigate the effect of TMAO on the progression of hepatocellular carcinoma (HCC) in mice by promoting NLRP3 inflammasome activation and its underlying mechanisms. Methods: Twelve 6~8-week-old SPF-grade C57BL/6J mice were used to establish an orthotopic HCC model by intrahepatic inoculation of Hepa1-6 cells. The mice were randomly divided into a control group (NC group) and a TMAO group, with 6 mice in each group. One week after inoculation, the TMAO group was intraperitoneally injected with a TMAO solution, while the NC group received an equivalent volume of saline. Body weight changes were recorded during the experiment. Four weeks later, liver tumors were isolated, and their size and weight were measured to determine the effect of TMAO on tumor progression. Serum levels of IL-1β and IL-18 were detected, and pathological changes in liver tissues were observed using HE staining. The mRNA levels of NLRP3, Caspase-1, and GSDMD in liver tissues were measured by real-time quantitative PCR (RT-PCR). Results: The orthotopic HCC model was successfully established. Compared with the control group, TMAO promoted liver tumor growth (P < 0.05), increased serum levels of IL-1β and IL-18 (P < 0.05), and enhanced the mRNA expression of NLRP3, Caspase-1, and GSDMD in liver tissues (P < 0.05). Conclusion: TMAO promotes the progression of hepatocellular carcinoma by releasing inflammatory factors through the NLRP3/GSDMD signaling pathway.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3 |
| [3] | Cai, X., Chen, J., Xu, H., Liu, S., Jiang, Q., Halfmann, R., et al. (2014) Prion-like Polymerization Underlies Signal Transduction in Antiviral Immune Defense and Inflammasome Activation. Cell, 156, 1207-1222. https://doi.org/10.1016/j.cell.2014.01.063 |
| [4] | Li, Z., Ji, S., Jiang, M., Xu, Y. and Zhang, C. (2022) The Regulation and Modification of GSDMD Signaling in Diseases. Frontiers in Immunology, 13, Article 893912. https://doi.org/10.3389/fimmu.2022.893912 |
| [5] | Dai, B., Cao, H., Hu, Y., Gong, Z., Huang, X., Chen, Y., et al. (2023) Role of NLRP3 Inflammasome Activation in HCC Cell Progression. Heliyon, 9, e19542. https://doi.org/10.1016/j.heliyon.2023.e19542 |
| [6] | Liu, Z., Tan, X., Li, Q., Liao, G., Fang, A., Zhang, D., et al. (2018) Trimethylamine N-Oxide, a Gut Microbiota-Dependent Metabolite of Choline, Is Positively Associated with the Risk of Primary Liver Cancer: A Case-Control Study. Nutrition & Metabolism, 15, Article No. 81. https://doi.org/10.1186/s12986-018-0319-2 |
| [7] | Fang, Q., Zheng, B., Liu, N., Liu, J., Liu, W., Huang, X., et al. (2021) Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats with Diabetic Kidney Disease. Frontiers in Physiology, 12, Article 682482. https://doi.org/10.3389/fphys.2021.682482 |
| [8] | Yang, G. and Zhang, X. (2022) Trimethylamine N-Oxide Promotes Hyperlipidemia Acute Pancreatitis via Inflammatory Response. Canadian Journal of Physiology and Pharmacology, 100, 61-67. https://doi.org/10.1139/cjpp-2021-0421 |
| [9] | Xie, Y. and Liu, F. (2024) The Role of the Gut Microbiota in Tumor, Immunity, and Immunotherapy. Frontiers in Immunology, 15, Article 1410928. https://doi.org/10.3389/fimmu.2024.1410928 |
| [10] | Wang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., et al. (2022) The Microbial Metabolite Trimethylamine N-Oxide Promotes Antitumor Immunity in Triple-Negative Breast Cancer. Cell Metabolism, 34, 581-594.e8. https://doi.org/10.1016/j.cmet.2022.02.010 |
| [11] | Mirji, G., Worth, A., Bhat, S.A., El Sayed, M., Kannan, T., Goldman, A.R., et al. (2022) The Microbiome-Derived Metabolite TMAO Drives Immune Activation and Boosts Responses to Immune Checkpoint Blockade in Pancreatic Cancer. Science Immunology, 7, eabn0704. https://doi.org/10.1126/sciimmunol.abn0704 |
| [12] | Banerjee, R., Wehrle, C.J., Wang, Z., Wilcox, J.D., Uppin, V., Varadharajan, V., et al. (2024) Circulating Gut Microbe-Derived Metabolites Are Associated with Hepatocellular Carcinoma. Biomedicines, 12, Article 1946. https://doi.org/10.3390/biomedicines12091946 |
| [13] | Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A.X., Finn, R.S., Abecassis, M.M., et al. (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68, 723-750. https://doi.org/10.1002/hep.29913 |
| [14] | Tang, Y., Tao, Y., Zhu, L., Shen, J. and Cheng, H. (2023) Role of NLRP3 Inflammasome in Hepatocellular Carcinoma: A Double-Edged Sword. International Immunopharmacology, 118, Article 110107. https://doi.org/10.1016/j.intimp.2023.110107 |
| [15] | Liu, B., Zhou, Z., Jin, Y., Lu, J., Feng, D., Peng, R., et al. (2022) Hepatic Stellate Cell Activation and Senescence Induced by Intrahepatic Microbiota Disturbances Drive Progression of Liver Cirrhosis toward Hepatocellular Carcinoma. Journal for ImmunoTherapy of Cancer, 10, e003069. https://doi.org/10.1136/jitc-2021-003069 |
| [16] | Xiao, C., Gong, J., Jie, Y., Liang, W., Tai, Y., Qin, W., et al. (2023) E2F1-Mediated Up-Regulation of NCAPG Promotes Hepatocellular Carcinoma Development by Inhibiting Pyroptosis. Journal of Clinical and Translational Hepatology, 12, 25-35. https://doi.org/10.14218/jcth.2022.00292 |
| [17] | Liu, C., Wu, J., Li, Z., Huang, X., Xie, X. and Huang, Y. (2024) Cinobufotalin Inhibits Proliferation, Migration and Invasion in Hepatocellular Carcinoma by Triggering NOX4/NLRP3/GSDMD-Dependent Pyroptosis. Frontiers in Oncology, 14, Article 1438306. https://doi.org/10.3389/fonc.2024.1438306 |
